Trial Profile
A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Niraparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 22 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 27 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.